MET expression during prostate cancer progression

Tyrosine-kinase inhibitors of the hepatocyte growth factor receptor MET are under investigation for the treatment of hormone-refractory prostate cancer (HRPC) metastasis. Analysis of MET protein expression and genetic alterations might contribute to therapeutic stratification of prostate cancer pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Verhoef, Esther I., Kolijn, Kimberley, De Herdt, Maria J., van der Steen, Berdine, Hoogland, A. Marije, Sleddens, Hein F.B.M., Looijenga, Leendert H.J., van Leenders, Geert J.L.H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058736/
https://www.ncbi.nlm.nih.gov/pubmed/27105539
http://dx.doi.org/10.18632/oncotarget.8829

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058736/
https://www.ncbi.nlm.nih.gov/pubmed/27105539
http://dx.doi.org/10.18632/oncotarget.8829

Ejemplares similares